Becton Dickinson’s combination test for COVID-19 gets FDA authorization

PUBLISHED: Fri, 12 Feb 2021 12:10:36 GMT
Share

Feb 12 (Reuters) – The U.S. Food and Drug Administration has granted emergency use authorization to a molecular test from Becton Dickinson that can detect viruses that cause COVID-19 as well as influenza and produce results in 2-3 hours, the company said on Friday.

Sign Up for Our Newsletter Daily Update

Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.

The authorization includes updated information in the test’s instructions for use that addresses variants of the SARS-COV-2 virus, including variants from the U.K. and South Africa. (Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)

(c) Copyright Thomson Reuters 2021. Click For Restrictions – https://agency.reuters.com/en/copyright.html

,